Navigation Links
MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
Date:4/11/2011

SAN DIEGO, April 11, 2011 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). The initial year 1 grant of $150,000 was awarded on August 1, 2010 and supported the manufacture and testing of the company's sarcoma vaccine currently in clinical testing. The follow-on grant is intended to help support the Phase II clinical trial of the company's vaccine to prevent recurrent sarcoma.  The year 2 award is for $974,000 and the year 3 award is for an additional $878,000.  

"We are very gratified that the NCI has made this follow-on award to MabVax.  These grants will significantly help offset the costs of the Phase II trial such as investigational site and certain patient care expenses," said David Hansen, CEO of MabVax.  He added that "the trial now has 10 active sites enrolling patients and we have made good progress toward reaching our enrollment goals."

The Phase II clinical trial will enroll a total of 134 metastatic sarcoma patients in a randomized, multicenter, double-blind study of the trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent sarcoma.  In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of the disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination t
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... On August ... inviting a diverse selection of entrepreneurs from across the United States to talk about ... Richman is honored to be chosen to be among the attendees. , One of ...
(Date:8/4/2015)... 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... China , today announced that it will release ... June 30, 2015, after market close on Wednesday, August ... Thursday, August 13, 2015, at 8:00 a.m. EDT (Thursday, ... to review the Company,s financial results and provide an ...
(Date:8/3/2015)... , Aug. 3, 2015  ArroGen Group, an ... new Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 ... in Sacramento, Calif. ... will enable law enforcement agents, district attorneys and ... criminal suspects. By analyzing chemical residues ...
(Date:8/3/2015)... MARIETTA, Ga. , Aug. 3, 2015  MiMedx ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... will present at the 35 th Annual Canaccord|Genuity ...  Parker H. "Pete" Petit, Chairman and CEO, William ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2
... 12 Eli Lilly and Company (NYSE: LLY ... the 45th Annual Meeting of the American Society of Clinical ... 2, 2009, with the majority of the presentations continuing to ... will present the latest research findings on ALIMTA(R) (pemetrexed for ...
... , - For the ... use CPMRC,s Interdisciplinary Clinical Content Through TSG,s Integrated,Portal Solutions ... and The Shams Group (TSG) have partnered to,provide small- ... integrates with their current health,information systems. , ...
... MSEDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... sclerosis (MS), today announced financial and operational results for ... remain on track to obtain the results from MAESTRO-01, ... in patients with secondary progressive multiple sclerosis, in the ...
Cached Biology Technology:Lilly Set to Unveil More Than 50 Studies at ASCO 2009 2Lilly Set to Unveil More Than 50 Studies at ASCO 2009 3Lilly Set to Unveil More Than 50 Studies at ASCO 2009 4Lilly Set to Unveil More Than 50 Studies at ASCO 2009 5Lilly Set to Unveil More Than 50 Studies at ASCO 2009 6CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 2CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 3CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 4BioMS Medical Announces First quarter 2009 results 2BioMS Medical Announces First quarter 2009 results 3BioMS Medical Announces First quarter 2009 results 4BioMS Medical Announces First quarter 2009 results 5BioMS Medical Announces First quarter 2009 results 6BioMS Medical Announces First quarter 2009 results 7BioMS Medical Announces First quarter 2009 results 8BioMS Medical Announces First quarter 2009 results 9
(Date:7/31/2015)... , 31 de julio de 2015 La ... ) se celebrará por medio de BGI del 22 al 25 ... . Este año, la conferencia celebra su ... se ha convertido en una de las reuniones anuales más ... una de las reuniones más dinámicas, entusiastas y mejores a ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... A&M University and University of North Carolina School of ... of diet complexity and estrogen hormone receptors on intestinal ... promoting the growth of certain beneficial intestinal microorganisms can ... determine the effect,of certain factors on intestinal microbiota. ...
... are already used in the displays of smart phones or ... high contrast, but come with a serious drawback: typically, only ... device is actually converted into light. This ratio can be ... or iridium to the active material, but these elements are ...
... An international team of researchers, co-led by scientists at ... produced the first multi-disciplinary evidence for management of cattle ... domestication took place in the Near East, over 10,000 ... achievement in human history. Until now, researchers believed that ...
Cached Biology News:Gut reaction 2Novel LEDs pave the way to cheaper displays 2Researchers uncover origins of cattle farming in China 2
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... and convenience from the former kit #17295. However, ... problem but also produced some advantages as follows. ... HRP conjugated antibody from lyophilized product to liquid ... of the conjugate has improved so that the ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
... low melting point agarose where separation is ... for separation of nucleic acids less than ... Micro ABgarose is also suited to capillary ... techniques. At a 3% concentration, Micro ABgarose ...
Biology Products: